IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11802161 B1

PDFFull Text
Date of Patent:
Oct. 31, 2023

Filed:

Mar. 13, 2019

Anti-cd25 for tumour specific cell depletion

Applicants:

Tusk Therapeutics Ltd., Hertfordshire, GB;

Cancer Research Technology Limited, London, GB;

Inventors:

Anne Goubier, Hertfordshire, GB;

Beatriz Goyenechea Corzo, Hertfordshire, GB;

Josephine Salimu, Hertfordshire, GB;

Kevin Moulder, Hertfordshire, GB;

Pascal Merchiers, Hertfordshire, GB;

Mark Brown, Hertfordshire, GB;

James Geoghegan, Lyme, NH (US);

Bianka Prinz, Lebanon, NH (US);

Sergio Quezada, London, GB;

Assignees:

Tusk Therapeutics Ltd., Hertfordshire, GB;

Cancer Research Technology Limited, London, GB;

Attorneys:

Choate, Hall & Stewart LLP

Brenda Herschbach Jarrell

Michael L. Vetter

Primary Examiner:

Julie Wu

Assistant Examiner:

Francesca Edgingtongiordan

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/02 (2006.01); C12N 15/85 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 14/55 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/39533 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 39/39566 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/55 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2015/8518 (2013.01);
Abstract

The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Find Patent Forward Citations

Loading…